NYSE:CI Key Ratios
| Market Cap $ M | 74,227.79 |
| Enterprise Value $ M | 99,226.79 |
| P/E(ttm) | 11.62 |
| PE Ratio without NRI | 8.92 |
| Forward PE Ratio | 8.38 |
| Price/Book | 1.74 |
| Price/Sales | 0.26 |
| Price/Free Cash Flow | 8.21 |
| Price/Owner Earnings | 8.62 |
| Payout Ratio % | 0.20 |
| Revenue (TTM) $ M | 281,336.00 |
| EPS (TTM) $ | 24.17 |
| Beneish M-Score | -2.56 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 1.10 |
| y-y EBITDA Growth Rate % | 20.70 |
| EV-to-EBIT | 9.86 |
| EV-to-EBITDA | 7.76 |
| PEG | 8.11 |
| Shares Outstanding M | 264.24 |
| Net Margin (%) | 2.28 |
| Operating Margin % | 3.17 |
| Pre-tax Margin (%) | 3.07 |
| Quick Ratio | 0.74 |
| Current Ratio | 0.85 |
| ROA % (ttm) | 4.12 |
| ROE % (ttm) | 15.38 |
| ROIC % (ttm) | 6.42 |
| Dividend Yield % | 2.20 |
| Altman Z-Score | 2.78 |
CI Number of Guru Trades
CI Volume of Guru Trades
Gurus Latest Trades with NYSE:CI
NYSE:CI is held by these investors
The Cigna Group Insider Transactions
Guru Commentaries on NYSE:CI
Cigna (+19.7%) delivered strong gains in the quarter following better-than-expected fourth quarter earnings, driven by continued strength in the Evernorth pharmacy benefit segment. Management reaffirmed 2025 guidance and announced leadership changes, including the promotion of Brian Evanko to Chief Operating Officer. With the Medicare divestiture complete, the company is focused on streamlining operations and improving margins. While elevated medical loss ratios persist in stop-loss, repricing is underway and core earnings growth is expected to accelerate in 2026.
Cigna Group, a manager of health care plans, benefited from the market’s perception that it is a more stable investment option than other health insurance companies in the current environment, given its minimal exposure to federal government spending and relatively low exposure to insurance risk. This stability has made it an attractive choice for investors amid economic uncertainty, contributing positively to its performance during the quarter.
In March, we purchased additional shares of Cigna (CI) in accounts that were underweighted in this position. This decision reflects our confidence in Cigna's business model and growth potential within the health care sector. The company's strong fundamentals and market position suggest it is well-equipped to navigate the evolving landscape of health care services, making it a valuable addition to our portfolio.
News about NYSE:CI
Total 0- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
